MSCI USA IMI Genomic Innovation Select 50 Index
The MSCI USA IMI Genomic Innovation Select 50 Index is based on the MSCI USA IMI Index, its parent index, and includes large, mid and small-cap securities of the U.S equity markets. The Index aims to represent the performance of a set of companies that are expected to derive significant revenues, based on the underlying index methodology criteria, from the development of new products and services in the field of genomic sequencing, synthesis, analysis or instrumentation, enable bio computing, bioinformatics, molecular diagnostics and agricultural biotechnology.
Data as of Sept. 30, 2024
ESG metrics
Summary
MSCI USA IMI Genomic Innovation Select 50 Index
Implied Temperature Rise
> 1.5°C - < 2°C
92.00% coverage
MSCI ACWI IMI
Implied Temperature Rise
> 2.0°C - < 3.2°C
94.69% coverage
(*) Additional ESG factor not mentioned in the regulation but provided for transparency purposes.
Data available as of Sept. 30, 2024. The information was updated as part of the regular monthly update cycle.
MSCI ESG and climate ratings, research and data are produced by MSCI ESG Research LLC, a subsidiary of MSCI Inc. MSCI ESG Indexes, Analytics, Real Assets, and Private Capital Solutions are products of MSCI Inc. that utilize information from MSCI ESG Research LLC. MSCI Indexes are administered by MSCI Limited and MSCI Deutschland GmbH.